Holland · Neurology 2012 · systematic review and clinical practice guideline · n=15 studies

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Cited 345 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and evidence-based practice guideline assessing randomized and controlled clinical trials

PubMed 22529203 · doi:10.1212/WNL.0b013e3182535d0c · record verified 2026-08-29

What was done

The Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society conducted a systematic review to update clinical guidelines on NSAIDs and complementary treatments for episodic migraine prevention in adults. The authors searched literature from June 1999 to May 2009. From 284 screened abstracts, 49 Class I or Class II studies on migraine prevention were identified, of which 15 examined NSAIDs, nontraditional, or complementary therapies.

What was found

The abstract reports evidence-based recommendation levels rather than pooled numeric effect sizes: - Level A (effective): Petasites (butterbur) reduces migraine attack frequency and severity. - Level B (probably effective): Fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, MIG-99 (feverfew), magnesium, riboflavin, and subcutaneous histamine. - Level C (possibly effective): Cyproheptadine, Co-Q10, estrogen, mefenamic acid, and flurbiprofen. - Inadequate/conflicting data: Aspirin, indomethacin, omega-3, and hyperbaric oxygen. - Level B (probably ineffective): Montelukast.

Why it matters

This guideline clarifies which over-the-counter NSAIDs, nutraceuticals, and complementary interventions have rigorous clinical trial evidence for episodic migraine prophylaxis, guiding non-traditional treatment choices.

Limits

The abstract provides categorical recommendation grades rather than quantitative effect sizes, absolute risk reductions, or safety data. The search was limited to a 10-year window (1999–2009). The total number of enrolled participants across the 15 included studies is not reported in the abstract.

Cited by